Sign In
Buy ADUS
$88.49
-1.96 (-2.17%)
At Close: Jun 03, 2026
Addus HomeCare Announces First-Quarter 2020 Preliminary Earnings Release and Conference Call
08:05pm, Wednesday, 29'th Apr 2020
Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release preliminary earnings for the first quarter ended March 31, 2020, on Monday, May 4, 2
Oppenheimer Believes Humana (HUM) Won't Stop Here
12:16pm, Wednesday, 29'th Apr 2020
In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana (HUM), with a price target of $400.00. The company's
Oppenheimer Believes Humana (NYSE: HUM) Won’t Stop Here
12:16pm, Wednesday, 29'th Apr 2020
In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana (HUM – Research Report), with
Frauenring: Frauen brauchen in der Corona-Krise dringend mehr Unterstützung!
09:40am, Wednesday, 29'th Apr 2020
Aufstockung der Mittel für Fraueneinrichtungen auf 210 Millionen Euro zur Krisenbewältigung sofort notwendig
Community Health (CYH) Gets a Buy Rating from Oppenheimer
12:38am, Wednesday, 29'th Apr 2020
In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health (CYH), with a price target of $8.00. The
Community Health (CYH) Gets a Buy Rating from Oppenheimer
12:38am, Wednesday, 29'th Apr 2020
In a report released yesterday,
Michael Wiederhorn
from Oppenheimer maintained a
Buy
rating on Community Health (
CYH
–
Research Report
), with a price target of
$8.00
. The company’s shares close
Chemed (CHE) Receives a Rating Update from a Top Analyst
12:27am, Wednesday, 29'th Apr 2020
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE) yesterday and set a price target of $535.00. The company's shares closed
Chemed (CHE) Receives a Rating Update from a Top Analyst
12:27am, Wednesday, 29'th Apr 2020
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE – Research Report) yesterday and set a price target
Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Moderna (MRNA)
11:55am, Tuesday, 28'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Centene (CNC) and Moderna (MRNA) with bullish sentiments.
Analysts Offer Insights on Healthcare Companies: Centene (NYSE: CNC) and Moderna (NASDAQ: MRNA)
11:55am, Tuesday, 28'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Centene (
CNC
–
Research Report
) and Moderna (
MRNA
–
Research Report
) with bullish sentiments.
C
Amedisys (AMED) Receives a Rating Update from a Top Analyst
12:32pm, Monday, 27'th Apr 2020
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Amedisys (AMED) today and set a price target of $215.00. The company's shares closed
Amedisys (AMED) Receives a Rating Update from a Top Analyst
12:32pm, Monday, 27'th Apr 2020
Oppenheimer analyst
Michael Wiederhorn
maintained a
Buy
rating on Amedisys (
AMED
–
Research Report
) today and set a price target of
$215.00
. The company’s shares closed last Friday at $186.50.
Bank of America Corp DE Sells 2,279 Shares of Addus Homecare Co. (NASDAQ:ADUS)
08:42am, Wednesday, 22'nd Apr 2020
Bank of America Corp DE trimmed its holdings in shares of Addus Homecare Co. (NASDAQ:ADUS) by 13.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securiti
Addus Homecare (NASDAQ:ADUS) Rating Reiterated by Royal Bank of Canada
07:18am, Wednesday, 22'nd Apr 2020
Addus Homecare (NASDAQ:ADUS)‘s stock had its “buy” rating reaffirmed by analysts at Royal Bank of Canada in a report released on Monday, AnalystRatings.com reports. They presently have a $98.00
HCA Healthcare (HCA) Received its Third Buy in a Row
01:37pm, Tuesday, 21'st Apr 2020
After Credit Suisse and Barclays gave HCA Healthcare (NYSE: HCA) a Buy rating last month, the company received another Buy, this time from Oppenheimer.
